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ABSTRACT The dopamine transporter (DAT) plays an
important role in calibrating the duration and intensity of
dopamine neurotransmission in the central nervous system.
We have used a strain of mice in which the gene for the DAT
has been genetically deleted to identify the DAT’s homeostatic
role. We find that removal of the DAT dramatically prolongs
the lifetime (300 times) of extracellular dopamine. Within the
time frame of neurotransmission, no other processes besides
diffusion can compensate for the lack of the DAT, and the
absence of the DAT produces extensive adaptive changes to
control dopamine neurotransmission. Despite the absence of
a clearance mechanism, dopamine extracellular levels were
only 5 times greater than control animals due to a 95%
reduction in content and a 75% reduction in release. Para-
doxically, dopamine synthesis rates are doubled despite a
decrease of 90% in the levels of tyrosine hydroxylase and
degradation is markedly enhanced. Thus, the DAT not only
controls the duration of extracellular dopamine signals but
also plays a critical role in regulating presynaptic dopamine
homeostasis. It is interesting to consider that the switch to a
dopamine-deficient, but functionally hyperactive, mode of
neurotransmission observed in mice lacking the DAT may
represent an extreme example of neuronal plasticity resulting
from long-term psychostimulant abuse.
Dopamine is an important regulator of many physiological
functions, including control of locomotion, cognition, affect,
and neuroendocrine hormone secretion (1, 2). In the central
nervous system, dopamine signaling is governed by a balance
between the amount released, the duration of effects, and the
responsiveness of receptors. The dopamine transporter is
thought to play a central role in determining the duration of
action of dopamine by rapidly taking up extracellular dopa-
mine into presynaptic terminals after release (3). Differences
in the number of uptake sites (4) in different brain regions
provides dopamine with different extracellular lifetimes (5),
which allows its diffusion to remote receptor sites (6). Fur-
thermore, dopamine uptake rates are lowered by drugs of
abuse such as cocaine and amphetamines, and this action is
responsible for their stimulatory effects on behavior (7–9). In
addition to the dynamic processes that govern dopamine
neurotransmission, in the long term, dopamine is eventually
inactivated by the degradative enzymes monoamine oxidase
(MAO) and catechol-O-methyltransferase (COMT) (10).
The physiological importance of the DAT has been mostly
inferred from the behavioral and psychosocial effects of
pharmacological agents that interfere with dopamine trans-
port, such as psychostimulants and antidepressants. To exam-
ine the importance of the DAT, we created a strain of mice
lacking the dopamine tranporter protein using homologous
recombination (11). The most obvious phenotype of these
genetically modified animals is their marked spontaneous
hyperlocomotion, which is similar to animals on high doses of
psychostimulants. In this work, we examine the underlying
biochemical changes that accompany this genetic alteration.
Although the contribution of the DAT to the dynamics of
dopamine in the extracellular space is well appreciated, this
work reveals the central role of the DAT in the regulation of
presynaptic dopamine function. The data show that the DAT
not only regulates the lifetime of extracellular dopamine but,
rather unexpectedly, is critically involved in maintaining the
delicate balance between dopamine synthesis, release, and
degradation.
MATERIALS AND METHODS
Animals. C57BL/129SvJ wild-type mice (DAT1/1) and their
littermates heterozygous (DAT1y2) and homozygous
(DAT2y2) for DAT deletion were obtained by homologous
recombination as described previously(11) and used between
the ages of 2–4 months for the experiments described. They
were housed in an animal care facility at 23°C on a 12-hour
light/12-hour dark cycle and given food and water ad libitum.
They were caged with approximately three other littermates of
the same sex. Animal care and experimental protocols were in
accordance with institutional guidelines.
Cyclic Voltammetry in Brain Striatal Slices. Mice were
decapitated and their brains were rapidly removed. Brain slices
(400 mm thick) were prepared with a microtome, placed in a
recording chamber, and superfused with an artificial cerebro-
spinal f luid (12). Carbon-fiber electrodes were prepared as
described (13). Cyclic voltammograms (Einit 5 20.4 V, Eswitch
5 1.0 V, 300 V/s) were repeated every 100 ms. The oxidation
current for dopamine (0.5–0.7 V) was converted to concen-
tration by electrode calibration at the end of the experiment.
Dopamine release was evoked by single pulse stimulations
from an adjacent stimulating electrode (12). The rates of
uptake of extracellular dopamine in DAT1/1 and DAT1y2
mice were evaluated with the Michaelis–Menten equation
(12). Time courses in homozygote (DAT2y2) mice were
evaluated as a pseudo first-order rate constant (k). To compare
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kinetics between types of animals, a rate constant k was
calculated by dividing Vmax by Km values in DAT1/1 and
DAT1y2 mice.
In Vivo Microdialysis. Brain microdialysis (14) was per-
formed in the striatum of freely moving mice using concentric
microdialysis probes (2 mm membrane length; cut off 6,000
Da; CMA-11, CMA/Microdialysis, Solna, Sweden). Stereo-
taxic coordinates were: AP 0.0; DV 24.4; L 2.5 for DAT1/1
and DAT1y2 mice and AP 0.0; DV 23.2; L 1.8 for DAT2y2,
relative to bregma (15). Approximately 24 hours after surgery,
the dialysis probe was perfused at 0.8 ml/min with artificial
cerebral spinal f luid [150 mM Na1/3.0 mM K1/1.4 mM
Ca21/0.8 mM Mg21/31.0 mM PO42/155 mM Cl2 (ESA, Bed-
ford, MA)/0.25 mM ascorbate (pH 7.3)]. Perfusate samples
were collected every 20 min. After basal dopamine levels were
established, different dopamine concentrations were perfused
through the probe and loss or gain of dopamine was measured
(16, 17). Measurements of dopamine and metabolites in
microdialysis samples were by HPLC with electrochemical
detection (HPLC/EC) with a microbore column (5 mm parti-
cles, Unijet C18, 1 3 150 mm, BAS, West Lafayette, IN) and
electrochemically detected with a Unijet (3 mm) electrode.
The mobile phase contained 50 mM sodium citrate, 10 mM
NaH2PO4, 0.5 mM octyl sodium sulfate, 0.1 mM EDTA, and
17% methanol, at pH 3.5.
Biochemical Assays. Tissue content of catecholamines in
striatal homogenates was measured by HPLC/EC (column:
Ultremex 3 C18 IP, 100 3 4.6 mm, Phenomenex, Chicago)
using the same mobile phase as with microdialysis.
The in vivo rate of dopamine biosynthesis was determined by
the accumulation of striatal L-dihydroxyphenylalanine (L-
DOPA) 40 min after administration of 3-hydroxybenzylhy-
drazine (NSD-1015, 100 mg/kg i.p.) (18). L-DOPA was deter-
mined by HPLC/EC with the following mobile phase: 50 mM
NaH2PO4, 0.2 mM octyl sodium sulfate, 0.1 mM EDTA, and
10% methanol. To inhibit tyrosine hydroxylase (TH), a-meth-
yl-p-tyrosine (a-MPT, 250 mg/kg i.p.) was administered and
striatal dopamine content was determined by HPLC/EC 1 hour
later. Maximal TH activity was assayed in striatal homogenates
by the accumulation of L-DOPA after administration of
NSD-1015 in the presence of saturating concentrations of
tyrosine and cofactor BH4 (19).
The activity of soluble COMT in mouse striatal homoge-
nates was determined with 3,4-dihydroxybenzoic acid as the
substrate at a saturating concentration (400 mM) (20). The
O-methylated products of the reaction were determined with
HPLC/EC. Maximal in vitro MAO activity was determined in
striatal homogenates (21) with 50 mM dopamine as a saturat-
ing concentration of substrate. The product, 3,4-dihydroxy-
phenylacetic acid (DOPAC), was quantitated by HPLC as
described. Vesicular uptake of [3H]DA (New England Nu-
clear) during a 5-min incubation at 37°C (22) and binding of
[3H]dihydrotetrabenazine (Amersham) during a 60-min incu-
bation at 25°C were assessed in crude vesicle preparations (23)
from at least three animals in each group per assay. No
significant differences were found between DAT1/1 and
DAT2y2 mice.
To determine protein levels of TH, protein extracts (50 mg)
from wild-type, heterozygote, and homozygote striata (n 5 3
each group) were electrophoresed on 12% SDS/polyacryl-
amide gels and transferred to nitrocellulose. TH was identified
by standard Western blotting techniques using a monoclonal
rat antibody from Incstar (Minnesota) and chemiluminescent
detection (Amersham). Autoradiograms were scanned with a
Howtek scanner at 1200 dpi and images were analyzed using
NIH IMAGE (Wayne Rasband).
Chemicals. d-Amphetamine, cocaine, and pargyline were
from Sigma. NSD-1015, desipramine, nomifensine, and
a-MPT were purchased from RBI (Natick, MA). Ro407592
was a gift from Hoffmann–LaRoche (Nutley, NJ), and fluox-
etine was a gift from Eli Lilly (Indianapolis). All drugs were
applied to brain slice preparations at a concentration of 10 mM
with the exception of desipramine (0.5 mM).
RESULTS AND DISCUSSION
Extracellular Regulation of Dopamine. Release and uptake
of dopamine were simultaneously assessed by dopamine mea-
surements with fast-scan cyclic voltammetry at carbon-fiber
microelectrodes implanted in brain striatal slices. In the ge-
netically modified mice, electrically stimulated dopamine re-
lease was decreased by about 75% (Fig. 1). In addition, the rate
of dopamine clearance, reported as a rate constant k, was 300
times slower in DAT2y2 mice relative to wild-type mice (0.05
FIG. 1. Time course of dopamine release and uptake in mouse striatal slices. (Upper) Individual recordings of dopamine efflux evoked by a
single electrical pulse in striatal slices from control (DAT1/1), heterozygote (DAT1y2), and homozygote (DAT2y2) mice as measured by cyclic
voltammetry (12) (E, data; solid lines, simulations). Pseudo-first order rate constants (k) for uptake are shown in inset. (Lower) Effects of various
drugs on stimulated dopamine efflux in striatal slices from DAT2y2 animals. Results after drug application are superimposed on the predrug
response. All drugs were applied at a concentration of 10 mM for 20 min, and none caused any measurable effect. Results are representative of
recordings from at least 4 different animals.
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s21 vs. 16 s21) (Fig. 1). In heterozygote mice, the clearance rate
constant was reduced by half (k 5 9 s21), consistent with the
roughly 50% reduction in DAT sites (11). The psychostimu-
lants cocaine and amphetamine (2) prolonged the clearance of
dopamine in striatal slices from wild-type and heterozygote
animals, but these agents were totally devoid of effects in slices
from DAT2y2 animals (Fig. 1 and Table 1). In DAT2y2 mice,
but also in wild-type and heterozygote mice, the rate of
dopamine clearance was unaltered by inhibitors of the sero-
tonin and norepinephrine transporters [f luoxetine and desi-
pramine, respectively (2); Fig. 1 and Table 1]. Furthermore,
selective inhibitors of dopamine degradative enzymes (ref. 24;
pargyline and Ro 407592) did not influence dopamine clear-
ance (Fig. 1 and Table 1). Thus, despite the protracted period
of time that dopamine persists in the extracellular space,
neither transporters for other monoamines nor degradative
enzymes can compensate for the absence of the DAT. Indeed,
the long time required for removal of a single bolus of
dopamine in DAT2y2 slices is similar to estimates for diffu-
sion-controlled clearance from a slice (25). Thus, other non-
DAT-mediated uptake systems for removal of extracellular
dopamine such as uptake into glial cells or other compart-
ments, long speculated and referred to as Uptake-2 (26, 27),
do not significantly contribute to dopamine clearance even in
the range of high extracellular concentrations.
The persistence of dopamine in the extracellular space
suggests that resting concentrations should be elevated. Be-
cause fast-scan cyclic voltammetry only assesses changes in
dopamine concentrations, basal levels were measured using
the quantitative technique of ‘‘no net flux’’ microdialysis (16,
17). In freely moving animals, a 5-fold higher concentration of
striatal extracellular dopamine in DAT2y2 (35 nM) versus
wild-type animals (7 nM) was found, and the dopamine
concentration in heterozygote animals was almost doubled (12
nM, Fig. 2). These continuously high extracellular dopamine
levels are of the same magnitude as those transiently measured
in normal mice treated with the psychostimulant cocaine (data
not shown). On the basis of the combined results from cyclic
voltammetry and microdialysis, the profile of extended dopa-
mine lifetime and increased extracellular concentration is
certainly consistent with the spontaneous hyperactivity phe-
notype of the DAT2y2 mice (11).
Intracellular Regulation of Dopamine. Because of the re-
markable changes in extracellular dopamine and the absence
of a presynaptic recycling process, we expected that the
function of the dopamine terminals might be effected. We
document that marked changes in the synthesis, storage, and
metabolism of dopamine occur in mice lacking the DAT. The
tissue content of dopamine in DAT2y2 striatum, as measured
by HPLC/EC, was found to be less than 5% of wild-type levels
(Fig. 3). However, dopamine terminals in the striatum were
intact, ruling out an anatomical abnormality as a cause for the
decrease (M.J. et al., unpublished observation). The extremely
low tissue content of dopamine was unexpected considering
the high basal extracellular levels of dopamine and the behav-
ioral and biochemical hyperactivity of these mice (11). When
compared with total tissue content, there is a 100-fold greater
ratio of extracellular to total dopamine in the mutant com-
pared with the wild-type mice. These data show that the
decrease in the number of DAT results in a large diminution
of the intracellular stores of dopamine, implying that the
reserve pools of dopamine are acutely dependent on recycled
extracellular dopamine. This contention is further strength-
ened if one considers that rates of synthesis of dopamine are
doubled in the mutant relative to normal animals (see below).
The rate limiting enzyme in dopamine synthesis is TH (2).
In vivo assays of TH activity, measured as L-DOPA accumu-
lation after inhibition of L-aromatic acid decarboxylase with
NSD-1015 (18), showed a doubling in the rate of dopamine
synthesis in DAT2y2 vs. wild-type animals (Fig. 4A). Also, a 1
hour in vivo treatment with a-MPT, an inhibitor of TH,
produced an almost 90% decrease in the already low tissue
levels of dopamine in the DAT2y2 mice, as well as similar
decreases in DOPAC and homovanillic acid (HVA) (data not
shown), whereas the same treatment produced only a marginal
FIG. 2. Basal extracellular concentrations of dopamine measured
in vivo. Concentrations of dopamine in the striatum of freely moving
mice determined using a quantitative microdialysis method (16, 17).
Data are given as the mean 6 SEM of the difference between the
concentration of dopamine applied to the dialysis probe in the
perfusate and that collected at the probe effluent. The point of zero
flux (‘‘no net flux’’), extrapolated by linear regression, represents the
concentration of dopamine at which diffusion into the probe equals
that out of the probe. These values, that provide the basal extracellular
concentration of dopamine, were 6.95 6 0.51 nM for DAT1/1; 12.2 6
0.79 nM for DAT1y2, and 34.5 6 3.22 nM for DAT2y2 mice. Four
animals were measured in each group. The slope of the lines yield the
apparent recovery of dopamine from the brain. Recovery is much
lower in the DAT2y2 (29 6 5%) than in wild-type (54 6 5%) or
heterozygote (52 6 4%) animals, in accord with theory for systems
without active transport (16).
Table 1. Effects of uptake and degradation enzyme inhibitors,
degradation enzyme activity, and 3-MT in normal and
mutant mice
Parameter DAT1y1 DAT1y2 DAT2y2
Uptake blockers,
kdrugykcontrol*
Cocaine (10 mM) 21 6 4.0† 22 6 7.1† 1.2 6 0.4
Amphetamine (10 mM) 27 6 5.0† 17 6 7.6† 0.9 6 0.1
Nomifensine (10 mM) 78 6 8.0† 42 6 9.0† 0.9 6 0.3
Desipramine (0.5 mM) 1.9 6 0.8 2.2 6 1.0 0.8 6 0.1
Fluoxetine (10 mM) 3.5 6 1.8 2.2 6 1.0 1.0 6 0.1
Degradation enzyme
inhibitors, kdrugykcontrol
Pargyline (10 mM) 2.5 6 0.5 1.8 6 0.7 1.2 6 0.2




MAO 32 32 8‡
COMT 0.61 0.55 0.57
Extracellular metabolite,
dialysate level
3-MT, nM 1.6 6 0.1 3.0 6 0.6‡ 6.0 6 1.1‡
Data represent mean 6 SEM of 4–6 experiments.
*Values of pseudo-first-order rate constants (k) for uptake were
measured by cyclic voltammetry.
†Significant difference from predrug value (P , 0.01), Student’s t test.
‡Significant difference from DAT1y1 value (P , 0.01), Student’s t
test.
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effect in wild-type animals (Fig. 4A). The high dependence of
DAT2y2 mice on ongoing synthesis of dopamine was readily
apparent after a-MPT or NSD-1015 administration because
both caused much more rapid sedation than in wild-type
animals (data not shown).
In contrast to the elevated synthesis rate, the levels of striatal
TH protein in DAT2y2 mice were found to be less than 10%
of wild-type levels (Fig. 4B) and, consistent with this, the
maximal TH activity measured in brain homogenates was 80%
lower in the DAT2y2 than in the wild type, but unaltered in
DAT1y2 mice (data not shown). Thus, the few TH molecules
present in the DAT2y2 mice are very efficient in converting
tyrosine to L-DOPA. This result may be partly due to the
absence of newly transported dopamine in the cytoplasm that
normally inhibits TH activity (28, 29). Additionally, the down-
regulation of presynaptic D2 receptors (11) in DAT2y2 mice
decreases another inhibitory route of TH activity and could
result in enhanced synthetic rates (30). The low tissue levels of
dopamine and the increased rate of dopamine synthesis, as well
as the behavioral and neurochemical observations after syn-
thesis inhibition, establish that dopaminergic activity in the
DAT2y2 mice is tightly coupled to synthesis.
Metabolism of Dopamine in Genetically Altered Mice. In
the absence of the DAT, metabolism of dopamine is also
altered. An extracellular product of COMT degradation of
dopamine, 3-methoxytyramine (3-MT), was nearly 400%
higher in DAT2y2 than in wild-type mice, as measured by in
vivo microdialysis (Table 1). Similarly, HVA, also an extracel-
lular COMT product, was increased to 350% of control in
striatal homogenates from DAT2y2 mice (Fig. 3). Because
there is a higher concentration of substrate, COMT produces
more metabolites, although the maximal rate of COMT ac-
tivity is the same as control (Table 1). Thus, in the absence of
uptake, a situation where released DA cannot be recycled by
neurons, COMT plays a proportionally increased role as a
compensatory mechanism to regulate extracellular dopamine
levels.
Surprisingly, tissue levels of DOPAC, an intracellular prod-
uct of MAO action on dopamine, which might be expected to
reflect the low intracellular dopamine tissue levels, are the
same in all three types of mice (Fig. 3). Because MAO is
predominantly intracellular, it has been difficult to distinguish
whether its primary source of substrate is dopamine, which is
newly uptaken or newly synthesized (2, 31, 32); however, when
uptake is removed, the main source of DOPAC must be newly
synthesized dopamine. Although these higher-than-expected
DOPAC levels are maintained by the enhanced synthesis of
dopamine described above, the fact that the maximal in vitro
activity of MAO is decreased by about 75% in the DAT2y2
mice (Table 1) bolsters the argument for the susceptibility of
newly synthesized dopamine to degradation. Impaired vesic-
ular packaging of dopamine does not contribute to the sensi-
tivity of newly synthesized dopamine to degradation, because
vesicular transporter binding and tetrabenazine-sensitive up-
take of dopamine are both unchanged in the DAT2y2 animals
(data not shown). The findings concerning synthesis, storage,
and metabolism all strongly suggest that in the normal situa-
tion recycled rather than newly synthesized dopamine contrib-
utes more significantly to the maintenance of vesicular stores
of dopamine, a notion not previously appreciated. This could
occur if, for example, uptake sites are normally spatially closer
to vesicles than to mitochondria, the site of MAO.
Characterization of DAT Heterozygotes. In the heterozy-
gotes, where uptake is halved, stimulated release is lowered to
a similar extent (Fig. 1), maintaining homeostasis of dopamine
function. Indeed, behaviorally, the DAT1y2 mice appeared
normal, with locomotor activity not significantly different
from wild-type animals (11). However, the neurochemical
FIG. 3. Tissue content of monoamines and metabolites. Amounts
of monoamines and metabolites were measured in striatal homoge-
nates. DOPAC/dopamine ratios were 0.06, 0.08, and 1.6 for DAT1/1,
DAT1y2, and DAT2y2 mice, respectively, and HVA/dopamine ratios
were 0.09, 0.3, and 4.3, respectively. Results are presented as mean 6
SEM of determinations from 10–12 animals. An asterisk (p) indicates
value is significantly different (P , 0.05) from corresponding value in
DAT1/1 mice as determined by Student’s t test.
FIG. 4. (A) Indices of dopamine synthesis. Synthesis rates of
dopamine (solid bars) and effect of a tyrosine hydroxylase inhibitor (2)
(aMPT) on tissue levels of dopamine (open bars) in normal (DAT1/1),
heterozygote (DAT1y2), and homozygote mice (DAT2y2). Results are
presented as the mean 6 SEM of determinations from 4 to 6 different
animals per genotype. (B) Western blot of TH in the striatum of
wild-type and mutant mice. TH labeling decreased by 59% and 96%
in heterozygote and homozygote striata, respectively, as compared
with wild-type values. Immunohistochemistry with a TH antibody
demonstrates that the decrease in TH protein levels is not due to the
destruction of dopamine neurons as these were present at normal
levels (M.J. et al., unpublished observation). An asterisk (p) indicates
value is significantly different (P , 0.05) from corresponding value in
DAT1/1 mice as determined by Student’s t test.
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adaptations in the DAT1y2 mice, which are all intermediate
between that of wild-type and homozygote animals, indicates
that the neuronal plasticity observed in DAT2y2 mice can even
occur in the presence of the transporter. These properties
suggest the DAT1y2 animals may also represent an appropri-
ate model to further study adaptive changes in response to
long-term blockade of DAT.
Importance of DAT in Dopamine Homeostasis. The neuro-
chemical and biochemical changes in response to the lack of
DAT have revealed points of control in dopamine dynamics,
the importance of which had not been apparent before. These
results provide a direct demonstration that the maintenance of
normal stores of dopamine are more critically dependent on
recycled rather than newly synthesized dopamine. These data
also suggest an important role for MAO in the metabolism of
newly synthesized dopamine. Thus, in the normal situation,
newly synthesized rather than recycled extracellular dopamine
may be preferentially degraded by MAO. In contrast to the
dramatic changes found in dopamine synthesis, metabolism,
storage, release, and clearance, other transporter systems
(glial, serotonin, or norepinephrine) did not adapt to com-
pensate for the deleted DAT. In addition, the profound
changes observed in the properties of TH in mice lacking the
DAT should help in elucidating which of the various postulated
mechanisms of regulation (33) contribute to the maintenance
of the physiological activity of TH.
The DAT is the primary determinant of the lifetime of
extracellular dopamine. In the DAT2y2 mice, a situation is
created where the volume effected by a single dopamine
terminal must be greatly increased. Considerable evidence
suggests that dopamine neurotransmission, even in the pres-
ence of a fully functional complement of DAT, normally
occurs over distances much greater than that delineated by
synaptic structures (10–20 mm) (5, 34, 35). In vivo in the
DAT2y2 mice, within the time required for clearance, dopa-
mine can be predicted to diffuse for millimeters. The new
properties of the system resemble the long-distance volume
transmission mode (6, 36) postulated for dopamine in the
medial prefrontal cortex, a brain region where uptake is
relatively inefficient, reserve pools of dopamine are very low,
release is tightly coupled to synthesis, and autoreceptor reg-
ulation of synthesis is negligible (35, 37). Indeed, regional
differences in the expression of the DAT, as found in the
striatum when compared with the medial prefrontal cortex or
amygdala (35), for example, appear to be the major determi-
nant of differences in intraneuronal homeostasis and mode of
neurotransmission, i.e., synaptic or volume transmission.
In the absence of the DAT, adaptive changes of an unex-
pected diversity and magnitude are concurrently induced in
the striatal dopaminergic system. These broad compensatory
changes illustrate the importance of the DAT not only in
terminating dopamine transmission, but in maintaining nor-
mal dopamine homeostasis and function. The switch to a novel
mode of dopamine neurotransmission in the mice with im-
paired dopamine uptake might represent an extreme case of
changes accompanying drug addiction. Indeed, recent evi-
dence in human cocaine (38, 39) and methamphetamine (40)
abusers suggests that dopamine deficits occur in brain regions
such as the striatum that are highly regulated by DAT, while
such changes are not seen in medial prefrontal cortex (39).
This brain dopamine deficiency has been suggested to result in
the long-term consequences of psychostimulant use including
extrapyramidal disturbances and dysphoric abstinence symp-
toms (41, 42). In addition to the well appreciated sensitization
theory of addiction, that focuses mainly on postsynaptic mech-
anisms (43), presynaptic alterations by drugs of abuse deserve
consideration. Such adaptive changes might also underlie the
delayed therapeutic effects of antidepressants, which also
block monoamine transporters. Our findings provide new
insights into dopamine regulation and suggest potential ave-
nues for therapeutic intervention.
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